Charles Schwab’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $92.5M | Buy |
1,616,020
+28,337
| +2% | +$1.55M | 0.01% | 833 |
|
|
2026
Q1 | $89.7M | Buy |
1,587,683
+163,971
| +12% | +$9.56M | 0.01% | 786 |
|
|
2025
Q4 | $84.6M | Buy |
1,423,712
+26,112
| +2% | +$1.42M | 0.01% | 808 |
|
|
2025
Q3 | $75.7M | Sell |
1,397,600
-158,517
| -10% | -$9.07M | 0.01% | 872 |
|
|
2025
Q2 | $85.5M | Buy |
1,556,117
+23,803
| +2% | +$1.4M | 0.01% | 747 |
|
|
2025
Q1 | $108M | Buy |
1,532,314
+108,806
| +8% | +$7.32M | 0.02% | 618 |
|
|
2024
Q4 | $93.6M | Buy |
1,423,508
+21,880
| +2% | +$1.47M | 0.02% | 702 |
|
|
2024
Q3 | $98.5M | Buy |
1,401,628
+55,699
| +4% | +$4.66M | 0.02% | 663 |
|
|
2024
Q2 | $111M | Buy |
1,345,929
+4,614
| +0.3% | +$384K | 0.02% | 595 |
|
|
2024
Q1 | $117M | Sell |
1,341,315
-37,582
| -3% | -$3.36M | 0.03% | 538 |
|
|
2023
Q4 | $133M | Buy |
1,378,897
+74,100
| +6% | +$6.56M | 0.03% | 450 |
|
|
2023
Q3 | $115M | Buy |
1,304,797
+33,592
| +3% | +$2.99M | 0.03% | 448 |
|
|
2023
Q2 | $110M | Buy |
1,271,205
+12,173
| +1% | +$1.15M | 0.03% | 474 |
|
|
2023
Q1 | $122M | Buy |
1,259,032
+17,052
| +1% | +$1.77M | 0.04% | 428 |
|
|
2022
Q4 | $129M | Buy |
1,241,980
+26,963
| +2% | +$2.53M | 0.04% | 399 |
|
|
2022
Q3 | $103M | Buy |
1,215,017
+12,907
| +1% | +$1.15M | 0.04% | 430 |
|
|
2022
Q2 | $99.6M | Buy |
1,202,110
+74,080
| +7% | +$5.9M | 0.03% | 455 |
|
|
2022
Q1 | $87M | Buy |
1,128,030
+27,091
| +2% | +$2.27M | 0.03% | 574 |
|
|
2021
Q4 | $97.3M | Buy |
1,100,939
+49,535
| +5% | +$4.09M | 0.03% | 541 |
|
|
2021
Q3 | $81.3M | Buy |
1,051,404
+435,084
| +71% | +$34.3M | 0.03% | 588 |
|
|
2021
Q2 | $51.4M | Buy |
616,320
+34,886
| +6% | +$2.77M | 0.02% | 849 |
|
|
2021
Q1 | $43.9M | Sell |
581,434
-112,796
| -16% | -$9.21M | 0.02% | 931 |
|
|
2020
Q4 | $60.9M | Buy |
694,230
+11,793
| +2% | +$935K | 0.02% | 666 |
|
|
2020
Q3 | $51.9M | Buy |
682,437
+60,022
| +10% | +$6.07M | 0.02% | 648 |
|
|
2020
Q2 | $76.8M | Buy |
622,415
+25,784
| +4% | +$2.56M | 0.04% | 443 |
|
|
2020
Q1 | $50.4M | Buy |
596,631
+21,061
| +4% | +$1.81M | 0.03% | 524 |
|
|
2019
Q4 | $48.7M | Buy |
575,570
+84,123
| +17% | +$6.35M | 0.03% | 653 |
|
|
2019
Q3 | $33.1M | Buy |
491,447
+23,637
| +5% | +$1.82M | 0.02% | 835 |
|
|
2019
Q2 | $40.1M | Buy |
467,810
+22,343
| +5% | +$1.91M | 0.02% | 684 |
|
|
2019
Q1 | $39.6M | Buy |
445,467
+26,427
| +6% | +$2.45M | 0.03% | 670 |
|
|
2018
Q4 | $35.7M | Buy |
419,040
+22,812
| +6% | +$2.17M | 0.03% | 606 |
|
|
2018
Q3 | $38.4M | Buy |
396,228
+20,862
| +6% | +$2.08M | 0.03% | 670 |
|
|
2018
Q2 | $35.4M | Buy |
375,366
+20,685
| +6% | +$1.81M | 0.03% | 674 |
|
|
2018
Q1 | $28.8M | Buy |
354,681
+18,782
| +6% | +$1.61M | 0.02% | 768 |
|
|
2017
Q4 | $30M | Buy |
335,899
+15,414
| +5% | +$1.34M | 0.02% | 706 |
|
|
2017
Q3 | $29.8M | Buy |
320,485
+22,242
| +7% | +$1.97M | 0.03% | 644 |
|
|
2017
Q2 | $27.1M | Buy |
298,243
+22,433
| +8% | +$2.04M | 0.03% | 648 |
|
|
2017
Q1 | $24.2M | Buy |
275,810
+21,621
| +9% | +$1.92M | 0.02% | 715 |
|
|
2016
Q4 | $21.1M | Buy |
254,189
+15,050
| +6% | +$1.29M | 0.02% | 731 |
|
|
2016
Q3 | $22.1M | Buy |
239,139
+14,020
| +6% | +$1.32M | 0.03% | 624 |
|
|
2016
Q2 | $17.5M | Buy |
225,119
+6,906
| +3% | +$587K | 0.02% | 714 |
|
|
2016
Q1 | $18M | Buy |
218,213
+9,126
| +4% | +$743K | 0.02% | 670 |
|
|
2015
Q4 | $21.9M | Buy |
209,087
+15,226
| +8% | +$1.59M | 0.03% | 564 |
|
|
2015
Q3 | $20.4M | Sell |
193,861
-108,777
| -36% | -$14.5M | 0.03% | 546 |
|
|
2015
Q2 | $41.4M | Buy |
302,638
+20,796
| +7% | +$2.58M | 0.06% | 329 |
|
|
2015
Q1 | $35.1M | Buy |
281,842
+46,385
| +20% | +$4.91M | 0.05% | 369 |
|
|
2014
Q4 | $21.3M | Buy |
235,457
+20,699
| +10% | +$1.72M | 0.03% | 506 |
|
|
2014
Q3 | $15.5M | Buy |
214,758
+10,417
| +5% | +$685K | 0.03% | 580 |
|
|
2014
Q2 | $12.7M | Buy |
204,341
+10,150
| +5% | +$613K | 0.02% | 664 |
|
|
2014
Q1 | $13.2M | Buy |
194,191
+17,258
| +10% | +$1.27M | 0.02% | 630 |
|
|
2013
Q4 | $12.4M | Buy |
176,933
+19,959
| +13% | +$1.36M | 0.02% | 598 |
|
|
2013
Q3 | $11.9M | Buy |
156,974
+17,949
| +13% | +$1.19M | 0.02% | 555 |
|
|
2013
Q2 | $8.26M | Buy |
+139,025
| New | +$8.66M | 0.02% | 664 |
|
Other funds holding BMRN
VPC
Charles Schwab's BMRN Position: Q2 2026 in Review
Charles Schwab increased its BioMarin Pharmaceuticals (BMRN) stake by 1.8% in Q2 2026, buying an estimated $1.55M and bringing the position to 1,616,020 shares worth $92.5M. The position accounts for 0.01% of the portfolio, ranked #833.
Charles Schwab first reported a position in BMRN in Q2 2013 and has held it in 53 quarters since. The position peaked at $133M in Q4 2023. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- Charles Schwab held 1,616,020 shares of BioMarin Pharmaceuticals worth $92.5M as of Q2 2026.
- Charles Schwab bought 28,337 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.55M.
- BioMarin Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #833 holding.
- Charles Schwab first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- Charles Schwab's BioMarin Pharmaceuticals position peaked at $133M in Q4 2023.
- 562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.